CAS NO: | 211096-49-0 |
包装 | 价格(元) |
10 mM * 1 mL in DMSO | 电议 |
5mg | 电议 |
10mg | 电议 |
25mg | 电议 |
50mg | 电议 |
100mg | 电议 |
200mg | 电议 |
生物活性 | SB-265610 is a selective, competitive, nonpeptide and allostericCXCR2antagonist. SB-265610 blocks rat cytokine-induced neutrophil chemoattractant-1 (CINC-1)-induced calcium mobilization and neutrophil chemotaxis withIC50s of 3.7 nM and 70 nM, respectively[1][2]. | ||||||||||||||||
IC50& Target[1] |
| ||||||||||||||||
体外研究 (In Vitro) | In vitro, SB-265610 antagonizes rat cytokine-induced neutrophil chemoattractant-1 (CINC-1)-induced calcium mobilization,IC50of 3.7 nM, and rat neutrophil chemotaxis in a concentration-dependent manner,IC50of 70 nM. SB-265610 reduces the antiapoptotic effect of CINC-1 to the levels of those untreated with CINC-1[1]. | ||||||||||||||||
体内研究 (In Vivo) | SB-265610 (2 mg/kg/day; i.p.; daily; for two weeks) treatment significantly inhibits the recruitment of Gr-1+CD11b+ cells to the mammary adenocarcinoma with Tgfbr2 deletion but not the control tumors[3].
| ||||||||||||||||
分子量 | 357.16 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C14H9BrN6O | ||||||||||||||||
CAS 号 | 211096-49-0 | ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 |
| ||||||||||||||||
溶解性数据 | In Vitro: DMSO : 50 mg/mL(139.99 mM;Need ultrasonic) 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
|